Other OTC Pharmaceuticals - Brazil

  • Brazil
  • In Brazil, the revenue in the Other OTC Pharmaceuticals market reached US$1.07bn in 2024.
  • It is projected to experience an annual growth rate of 1.63% (CAGR 2024-2029).
  • When compared globally, the in the United States generates the highest revenue, amounting to US$7,171.00m in 2024.
  • In terms of per capita revenue, in Brazil generates US$4.90 per person in 2024.
  • The demand for Other OTC Pharmaceuticals in Brazil is driven by the country's large population and increasing healthcare awareness.

Key regions: Europe, Germany, United States, Brazil, Australia

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Other OTC Pharmaceuticals market in Brazil is experiencing significant development and growth.

Customer preferences:
Customers in Brazil have shown a growing preference for over-the-counter (OTC) pharmaceutical products for various reasons. One key factor is the convenience and accessibility of these products, as they can be purchased without a prescription and are readily available in pharmacies and supermarkets. Additionally, customers appreciate the lower costs associated with OTC medications compared to prescription drugs. This affordability factor is particularly important in Brazil, where a significant portion of the population has limited access to healthcare services and relies heavily on self-medication.

Trends in the market:
The Other OTC Pharmaceuticals market in Brazil is witnessing several notable trends. Firstly, there is an increasing demand for OTC products that cater to specific health concerns, such as pain relief, cough and cold, digestive health, and skincare. This trend can be attributed to the rising awareness among consumers about self-care and the growing emphasis on preventive healthcare.Another significant trend is the expansion of product offerings in the OTC market. Pharmaceutical companies are introducing new and innovative products to meet the evolving needs of consumers. This includes the introduction of natural and herbal remedies, as well as products targeting specific demographic groups, such as children and the elderly.

Local special circumstances:
Brazil has a large and diverse population, which presents unique challenges and opportunities for the OTC Pharmaceuticals market. The country's vast geographical size and regional disparities in healthcare infrastructure and access to medical services contribute to the popularity of OTC products. In remote areas with limited healthcare facilities, OTC medications serve as a primary source of treatment for common ailments.Furthermore, the Brazilian government has implemented policies to promote the use of OTC medications as a means to reduce the burden on the public healthcare system. This includes the inclusion of certain OTC drugs in the list of essential medicines, making them more accessible and affordable to the general population.

Underlying macroeconomic factors:
Several macroeconomic factors are driving the development of the Other OTC Pharmaceuticals market in Brazil. One key factor is the country's improving economic conditions, which have resulted in a growing middle class with increased purchasing power. As a result, more consumers are able to afford OTC medications and are willing to invest in their health and well-being.Additionally, Brazil's aging population is contributing to the growth of the OTC market. With a larger proportion of elderly individuals, there is a higher demand for OTC products that address age-related health issues, such as joint pain and cardiovascular health.In conclusion, the Other OTC Pharmaceuticals market in Brazil is experiencing significant growth and development due to customer preferences for convenience and affordability, as well as the introduction of new product offerings. Local special circumstances, such as regional disparities in healthcare access and government policies, further contribute to the market's expansion. The underlying macroeconomic factors, including improving economic conditions and an aging population, also play a crucial role in driving the growth of the OTC market in Brazil.

Methodology

Data coverage:

Data encompasses B2C spend. Figures are based on the OTC Pharmaceuticals market values, representing revenues generated by both product sales which take place exclusively in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use data from national statistical offices, international institutions, trade associations, and self-medication associations. Next, we use relevant key market indicators and data from country-specific associations, such as consumer healthcare spending, out-of-pocket healthcare expenditure, health system accessibilities, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. Whereas this market covers only OTC drugs, the Statista Pharmaceuticals market covers both OTC and prescription drugs.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)